Abstract
We made a retrospective analysis of 85 patients with elevated serum CA 125 after surgery for ovarian cancer. Absolute CA 125 serum levels were a poor guide to prognosis. However, the ratio between the serum CA 125 after the first, second, or third course of treatment and the postoperative value was an excellent guide to prognosis. These were also independent and stable in the Cox Regression analysis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alagoz T, Buller RE, Berman M, Anderson B, Manetta A, DiSaia P (1994) What is a normal CA 125 level? Gynecol Oncol 53:93–97
Avall-Lundquist E, Sjövall K, Hansson L-O, Eneroth P (1992) Peri-and postoperative changes in serum levels of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases. Arch Gynecol Obstet 251:69–78
Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337
Bast RC, Klug TL, John ES, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (1983) A radioimmunoassay using monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887
Beattie GJ, Sturgeon C, Fisken J, Roulston JE (1993) The effect of surgery on the concentration of CA 125 in epithelial ovarian cancer. Ann Clin Biochem 30:402–403
Breitenecker G, Neunteufel W, Bieglmayer C, Kolbl H, Schieder K (1989) Comparison between tissue and serum content of CA 125, CA 19-9, and carcinoembryonic antigen in ovarian tumors. Int J Gynecol Pathol 8:97–102
Burg MEL van der, Lammes FB, Verweij J (1992) CA 125 in ovarian cancer. Neth J Med 40:36–51
Canney PA, Moore M, Wilkinson PM, James RD (1993) Ovarian cancer antigen CA 125. A prospective clinical assessment of its role of a tumor marker. Br J Cancer 50:765
Crombach G, Würz H (1985) Vergleichende Bestimmung von CA 125, TPA und CEA bei Patienten mit malignen epithelialen Ovarialtumoren. In: Greten H, Klapdor R (Hrsg) Neue tumorassoziierte Antigene. Thieme, Stuttgart pp 167
Fisken J, Leonhard RCF, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, Roulston JE (1993) The prognostic value of early CA 125 serum assay in epithelial ovarian carcinoma. Br J Cancer 68:140–145
Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR (1989) The prognostic significance of the half-life serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynecol 96:1395–1399
Kenemans P, Verstraeten AA, van Kamp GJ, Hilgers J (1994) CA 125 in the management of ovarian carcinoma (abstract #562). Ann Oncol 5:112
Kimura E, Murae M, Takanashi H, Yasuda M, Terashima Y, Furukawa T (1995) A multivariate analysis of serum CA 125 in patients with ovarian carcinoma: when should we measure it to predict prognosis? (Abstract # 56). Proc Annu Meet Am Soc Clin Oncol 14:89
Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast JC (1987) CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69:223–227
Liu PY, Alberts DS, Federico M, Hanningan EV, Garcia DJ, Rothenberg ML, Dorr AT (1995): CA 125 concentration 8 weeks after treatment initiation independently predicts survival in patients with advanced epithelial ovarian cancer (abstract # 735). Proc ASCO 14:226
Makar A, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG (1992) Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 79:1002–1010
Mogensen O, Brock A, Nyland MH (1993) CA 125 measurements in ovarian cancer patients during their first postoperative week. Int J Gynecol Cancer 3:54–56
Münstedt K, Vahrson H (1995) Efficacy of combined radio- and chemotherapeutic treatment of advanced ovarian cancer. Eur J Gynaecol Oncol 16:174–180
Pujade-Lauraine E, Piccart M, Rustin G, Lhommé C, Gore G, Ten Bokkel Huinink M, Fumoleau P, Oosterom A van, Kaye S, Belpomme D, Van Glabbeke M, Wander J, Chevallier B, Franklin H, Verweij J (1994) Comparison of CA 125 kinetics and WHO criteria to evaluate chemotherapy response (Abstract # 502). Ann Oncol 5:100
Redman CWE, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM (1990) Can early serum CA 125 resonse predict outcome in epithelial ovarian cancer? Eur J Cancer 26:593–596
Ron IG, Inbar M, Gelernter I, Lewysohn O, Ayalon D, Dale J, Chatchik S (1994) Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand 73:658–662
Rosen A, Sevelda P, Klein M, Spona J, Beck A (1990) A CA 125 score as a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet 247:125–129
Rustin G, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawew KD (1989) Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 7: 1667–1671
Sevelda P, Schemper M, Spona J (1989) CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 161:1213–1216
Vahrson H, Dolzycki E, Münstedt K (1993) Postoperative Strahlentherapie des Ovarialkarzinoms. In: Künzel W, Kirschbaum M (Hrsg) Gießener Gynäkologische Fortbildung. Springer, Berlin Heidelberg New York, S 287ff
Welander CE (1992) What do CA 125 and other antigens tell us about ovarian cancer biology? Acta Obstet Gynecol Scand 155:85–93
Yedema CA, Kenemans F, Voorhorst F, Bon G, Schijf C, Beex L, Verstraeten A, Hilgers J, Vermorken J (1993) CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 67:1361–1367
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Münstedt, K., Krisch, M., Sachsse, S. et al. Serum CA 125 levels and survival in advanced ovarian cancer. Arch Gynecol Obstet 259, 117–123 (1997). https://doi.org/10.1007/BF02505319
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02505319